Silver Book Fact

Galantamine, a cholinesterase inhibitor, delays Alzheimer’s patients’ need for full-time care, with overall cost savings estimated between $323 and $4,256 per patient.

Caro, Jaime, Denis Getsios, Kristen Migliaccio-Walle, Jack Ishak, and Wissam El-Hadi. Rational Choice of Cholinesterase Inhibitor for the Treatment of Alzheimer s Disease in Canada: A comparative economic analysis. BMC Geriatrics. 2003; 3(6). http://www.biomedcentral.com/1471-2318/3/6

Reference

Title
Rational Choice of Cholinesterase Inhibitor for the Treatment of Alzheimer s Disease in Canada: A comparative economic analysis
Publication
BMC Geriatrics
Publication Date
2003
Authors
Caro, Jaime, Denis Getsios, Kristen Migliaccio-Walle, Jack Ishak, and Wissam El-Hadi
Volume & Issue
Volume 3, Issue 6
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • An Alzheimer’s disease treatment breakthrough that slowed its progression and began to show its effects in 2015, would reduce the Medicare costs for people with the disease in 2050 by…  
  • Research shows that use of donepezil leads to a 4-fold increase in drug costs; however, it significantly lowers overall medical costs, reducing medical treatment and prescription drug costs by $3,891…  
  • An Alzheimer’s treatment breakthrough that slowed progression and began to show its effects in 2015, would reduce out-of-pocket costs to people with the disease by $25 billion in 2050–from the…  
  • 2006 Medicines in Development for Neurologic Disorders  
  • An Alzheimer’s treatment breakthrough that slowed disease progression and began to show effects in 2015, would reduce Medicaid costs for people with the disease by $62 billion–from the expected $178…